CLOV — Clover Health Investments, Corp.

Clover Health Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Membership Growth: Increased by 51% year-over-year, reaching approximately 156,000 members.
• Revenue: Total revenues of $749 million, up 62% year-over-year.
• GAAP Net Income: Reported at $27 million, a significant improvement of $29 million year-over-year.
• Adjusted EBITDA: Increased to $40 million, reflecting a 56% year-over-year growth.
• Consolidated Gross Profit: $160 million, up 47% year-over-year.
• Insurance Benefit Expense Ratio (BER): 86.5% for the quarter.
• Cash Position: Ended the quarter with $418 million in cash and investments, with no debt.

2. Strategic Updates and Business Highlights

• Market Position: Clover is now the largest PPO in New Jersey outside of special needs and employer retiree plans.
• Cohort Economics: Focus on long-term profitability through clinical integration and technology-driven care, particularly with the Clover Assistant platform.
• Operational Strategy: Moderated growth in the Open Enrollment Period (OEP) to prioritize clinical integration and operational readiness.
• Data Utilization: Expanded capabilities in data access and AI-driven insights, enhancing care management and operational efficiency.
• Counterpart Health: Investments in this division are aimed at creating long-term growth opportunities outside of the core insurance business.

3. Forward Guidance and Outlook

• 2026 Outlook: Confident in meeting or exceeding full-year guidance across all metrics, with a focus on strong retention and clinical engagement.
• Long-term Positioning: Anticipate that a significant portion of the membership base will progress favorably along the lifetime value curve, contributing positively to margins and cash generation.
• 2027 Planning: Early positive indicators for bids, with a focus on maintaining flexibility in growth versus margin strategies.

4. Bad News, Challenges, or Points of Concern

• New Member Costs: Initial costs associated with new member acquisition may create near-term headwinds.
• Outpatient Utilization: Elevated outpatient costs are a concern, although they are in line with expectations.
• Prior Year Development: Experienced some modest unfavorability related to prior year claims, which could impact future performance.
• Monitoring Risks: Ongoing evaluation of Part D performance and the impact of Counterpart Health investments.

5. Notable Q&A Insights

• SG&A Variability: Noted variability in SG&A due to one-time expenses related to membership growth and claims adjustment reserves.
• Cohort Health: New and existing cohorts are tracking well, with positive indicators in inpatient and dental utilization.
• RAF Scores: Current RAF scores are in line with expectations, providing confidence in future performance.
• G&A Guidance: No formal guidance on G&A was provided, but a commitment to 100-150 basis points of improvement for 2026 was reiterated.

Overall, Clover Health's Q1 2026 results reflect strong growth and profitability, with strategic initiatives aimed at enhancing member care and operational efficiency, although challenges remain in managing costs and monitoring cohort performance.